Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice

BMC Research Notes

Glenn Haugeberg¹  Dag Magnar Soldal²  Andreas P Diamantopoulos¹  Siv Grødal Eppeland² 

[1] Department of Neuroscience, Division of Rheumatology, Norwegian University of Science and Technology, Trondheim, 7489, Norway;Department of Rheumatology, Hospital of Southern Norway, Servicebox 416, Kristiansand.S, 4604, Norway

关键词: Health services;    Exercise therapy;    Rehabilitation;    Axial spondyloarthritis;    Ankylosing spondylitis;   

Others  :  1142760
DOI  :  10.1186/1756-0500-6-185

 received in 2012-10-05, accepted in 2013-04-30,  发布年份 2013

【 摘 要 】

Background

From a health service perspective, society, with its limited resources, needs to be reassured that evidence-based medicine is also effective when carried out in the frame of ordinary clinical practice. The effectiveness of rehabilitation programs in ankylosing spondylitis (AS) has been proven to be effective in clinical trials. However, less is known when this is carried out in clinical practice. The aim of this study was to evaluate the effect of a 2-weeks rehabilitation program on self-reported outcome and physical function in patients with axial spondyloarthritis (ax-SpA) including AS patients carried out in ordinary clinical practice. The program contained of daily water exercises, exercises for flexibility, muscle strength, and cardio-respiratory fitness.

Results

A total of 87 ax-SpA patients (60 men, 27 women), aged ≥ 18 years were identified to have participated in the 2-weeks in-patient rehabilitation program. Mean age was 49 years and disease duration was 14 years. 92.5% were HLA-B27 positive, 62% were current users of non-steroidal anti-inflammatory drugs, and 17% were current users of tumour necrosis factor inhibitors. After 2-weeks, a statistical significant improvement (p < 0.001) was observed for patient-reported outcomes (Bath Ankylosing Spondylitis (BAS) Disease Activity Index 4.3 vs. 3.1, BAS Functional Index 3.1 vs. 2.4) and physical measured outcomes (BAS Metrology Index 3.23 vs. 2.29, Gait Velocity 2.2 vs. 2.6 m/s, timed-stands test 22.5 vs. 16.3 s, finger-floor distance 17.9 vs. 8.9 cm, chest expansion 3.9 vs. 4.6 cm).

Conclusion

Data, from our retrospective case series report, support that patient with ax-SpA benefit from short-term rehabilitation when it is carried out in ordinary clinical care. Data from ordinary clinical care may be important when discussing the effectiveness of a treatment and allocating resources in the health care system.

【 授权许可】

   
2013 Eppeland et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J: The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
• [2]Van Der LS, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
• [3]Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442-452.
• [4]Zochling J, Braun J: Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. Expert Opin Pharmacother 2006, 7:869-883.
• [5]Toussirot E, Wendling D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998, 56:225-240.
• [6]Colina M, Ciancio G, Garavini R, Conti M, Trotta F, Govoni M: Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol 2009, 22:1125-1129.
• [7]van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M: Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001, 45:430-438.
• [8]Masiero S, Bonaldo L, Pigatto M, Lo Nigro A, Ramonda R, Punzi L: Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 2011, 38:1335-1342.
• [9]Fernandez-de-Las-Penas C, Alonso-Blanco C, Morales-Cabezas M, Miangolarra-Page JC: Two exercise interventions for the management of patients with ankylosing spondylitis: a randomized controlled trial. Am J Phys Med Rehabil 2005, 84:407-419.
• [10]Ince G, Sarpel T, Durgun B, Erdogan S: Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys Ther 2006, 86:924-935.
• [11]Staalesen Strumse YA, Nordvag BY, Stanghelle JK, Roisland M, Winther A, Pajunen PA: Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting. J Rehabil Med 2011, 43:534-542.
• [12]Klokkerud M, Hagen KB, Lochting I, Uhlig T, Kjeken I, Grotle M: Does the content really matter? A study comparing structure, process, and outcome of team rehabilitation for patients with inflammatory arthritis in two different clinical settings. Scand J Rheumatol 2012, 41:20-28.
• [13]van den Berg R, Baraliakos X, Braun J, van der Heijde D: First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology 2012, 51:1388-1396.
• [14]Dagfinrud H, Kvien TK, Hagen KB: Physiotherapy interventions for ankylosing spondylitis. Cochrane database of systematic reviews (Online) 2008, 1:CD002822.
• [15]Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
• [16]Curtis JR: Improving osteoporosis care through multimodal interventions: insights from the University of Alabama at Birmingham Center for Education and Research on Therapeutics. Osteoporos Int 2011, 22(Suppl 3):445-450.
• [17]Sung NS, Crowley WF Jr, Genel M, Salber P, Sandy L, Sherwood LM: Central challenges facing the national clinical research enterprise. JAMA 2003, 12:1278-1287.
• [18]Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
• [19]Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
• [20]Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994, 21:1694-1698.
• [21]Csuka M, McCarty DJ: Simple method for measurement of lower extremity muscle strength. Am J Med 1985, 78:77-81.
• [22]Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM: American college of sports medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011, 43:1334-1359.
• [23]van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005, 52:1205-1215.
• [24]van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591.
• [25]Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004, 63:1594-1600.
• [26]van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
• [27]Mathieu S, Gossec L, Dougados M, Soubrier M: Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 2011, 63:557-563.
• [28]Halvorsen S, Vollestad NK, Fongen C, Provan SA, Semb AG, Hagen KB: Physical fitness in patients with ankylosing spondylitis: comparison with population controls. Phys Ther 2012, 92:298-309.
• [29]Van Tubergen A, Boonen A, Landewe R, Rutten-Van Molken M, Van Der Heijde D, Hidding A: Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002, 47:459-467.
• [30]Dagfinrud H, Halvorsen S, Vollestad NK, Niedermann K, Kvien TK, Hagen KB: Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness? Arthritis Care Res 2011, 63:597-603.
• [31]Sokka T, Haugeberg G, Pincus T: Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective. Clin Exp Rheumatol 2007, 25(6 Suppl 47):86-97.
• [32]Waldner A, Cronstedt H, Stenstrom CH: The Swedish version of the Bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol Suppl 1999, 111:10-16.